Navigation Links
Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer
Date:8/28/2012

BATON ROUGE, La., Aug. 28, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that over‐express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over‐expressed in a wide range of cancers including ovarian cancer. In June, the Company presented results from the successful completion of a Phase 1 study of EP‑100 in advanced solid tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting.

"We are pleased with the continued momentum behind EP‑100 and the progress of enrollment as we begin the randomized treatment phase," said Dr. Hector Alila, CEO of Esperance. "We are encouraged with early results, and look forward to accelerating enrollment in a very important, underserved patient population and providing an update on the clinical progress over time."

The randomized, Phase 2 trial of EP‑100 in combination with paclitaxel versus paclitaxel alone in patients with histologically confirmed epithelial ovarian carcinomas expressing LHRH‐receptors is actively enrolling patients in key clinical sites across the United States. Rationale for the study is based on the positive clinical evidence from escalating doses in 38 patients in the Phase 1 study and on preclinical studies showing synergies between EP‑100 and various chemotherapeutic agents.

About EP‑100

EP‑100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP™) platform technology, is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over‐expressed in a wide range of cancers including breast, prostate, endometrial, pancreatic, ovarian, blood, skin and testicular cancers. Results from pre‐clinical studies of EP‑100 have shown that the drug regresses established tumors in breast, prostate, ovarian and endometrial cancer xenografts in mice.

About Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is a clinical stage company developing a new class of targeted anticancer drugs using its Cationic Lytic Peptide (CLYP™) platform technology. These drug candidates, called targeted membrane‐disrupting peptides (tMDPs) and antibody drug conjugates (ADCs) selectively seek and destroy cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. Targeting occurs through binding to specific receptors and antigens on the cell's surface. The Company was founded on patented technology discovered by scientists at the Pennington Biomedical Research Center, the Louisiana State (LSU) Ag Center and LSU main campus. Founding investors include the Louisiana Fund I, Themelios Ventures and Research Corporation Technologies. Additional investors include Sanofi, Advantage Capital Partners, Louisiana Technology Fund and private investors. More information can be found at www.esperancepharma.com.


'/>"/>
SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
2. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
3. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
4. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
5. Actinium Pharmaceuticals Strengthens Management Team
6. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
7. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
8. Access Pharmaceuticals To Host Second Quarter Investor Call on Thursday, August 23, 2012
9. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
10. Nouveau Life Pharmaceuticals (NOUV) Releases Calcium & Vitamin D for Strong Bones
11. Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... as senior vice president of sales, announced Andrea Heslin Smiley , VMS president ... business development and sales team, exploring new opportunities for VMS to empower patients and ... ... ... ...
(Date:5/24/2016)... , May 24, 2016 ... Education in Clinical Neurophysiology  Elsevier , ... products and services, today announced the launch of ... open access journal that focuses on clinical practice issues ... case reports, clinical series, normal values and didactic reviews. ...
(Date:5/23/2016)... , May 23, 2016 Global ... 163 pages, profiles 12 companies and the Paclitaxel analysis ... figures on the industry and its players. ... comprehensive in nature, details the current state of the ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... There are nearly 14.5 million people living with and beyond cancer in the ... 2016, communities around the world will gather to recognize these cancer survivors as part ... is an annual worldwide Celebration of Life that is held on the first Sunday ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eating Recovery Center, Washington ... opening a brand new child and adolescent residential treatment center on June 1. ... even more specialized eating disorder treatment and access to life-saving care. , To ...
(Date:5/26/2016)... New York, NY (PRWEB) , ... May 26, ... ... cell researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon ... Musculoskeletal Disease and Regeneration. The conference was held during May 5-6, 2016 in ...
(Date:5/26/2016)... Robles, CA (PRWEB) , ... May 26, 2016 , ... ... bunion (also knowns as a bunionette) treatment was more than humbled by customer demand ... of one of their SKU's mid sale. Now that Bunion Bootie has completely replenished ...
Breaking Medicine News(10 mins):